Proactive Investors - Run By Investors For Investors

Shares of CymaBay Therapeutics gain after study signals Seladelpar treatment shows 'efficacy'

The company now expects drug to advance to Phase 3 study
Assorted pills on table
The shares gained 11% on the study news

Shares of CymaBay Therapeutics Inc. (NASDAQ:CBAY) rose after the company said a study of its Seladelpar treatment for an autoimmune disease of the liver showed “compelling efficacy and tolerability.”

The stock advanced 11% to US$13.44.

The results from the Phase 2 study “support the potential for improved efficacy and better tolerability over existing second-line therapy,” the company said in a statement. CymaBay now expects the treatment to advance to Phase 3 in the second half of the year.

 

View full CBAY profile View Profile

CymaBay Therapeutics Timeline

Related Articles

technician's in a lab clean-room
March 12 2019
The Maryland company is seeing revenue surge through an expansion of contract manufacturing services, particularly in the area of CAR T-cell therapies
woman's face
Tue
Here we take a closer look at SkinBioTherapeutics, the life sciences group that is using bacteria to improve people’s skin
blood
June 21 2019
Belgium-based company’s Nu.Q test screens for colorectal and prostate cancers, and may have the potential to detect ovarian disease endometriosis
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use